Pfizer acquires Metsera for $10 billion, cementing their new obesity treatment strategy. The purchase concludes a weeklong bidding frenzy between the New York-based pharmaceutical company and Danish heavyweight Novo Nordisk, whose last-minute counterbid was finally rejected by US antitrust regulators. According to Reuters, Metsera’s board accepted a higher offer from Pfizer on Friday, citing regulatory











